View Future GrowthBCAL Diagnostics 과거 순이익 실적과거 기준 점검 0/6BCAL Diagnostics 의 수입은 연평균 -30.8%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 19.1%의 비율로 증가했습니다. 매출은 연평균 32.5%의 비율로 증가해 왔습니다.핵심 정보-30.83%순이익 성장률-15.81%주당순이익(EPS) 성장률Biotechs 산업 성장률9.61%매출 성장률32.52%자기자본이익률-286.61%순이익률-282.10%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.02 loss per share (vs AU$0.026 loss in FY 2024)Full year 2025 results: AU$0.02 loss per share. Net loss: AU$7.24m (loss widened 13% from FY 2024).Reported Earnings • Aug 31Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: AU$0.026 loss per share (further deteriorated from AU$0.024 loss in FY 2023). Revenue: AU$3.10m (up 8.6% from FY 2023). Net loss: AU$6.40m (loss widened 26% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 62%. Revenue is forecast to grow 78% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Reported Earnings • Feb 22First half 2024 earnings released: AU$0.01 loss per share (vs AU$0.012 loss in 1H 2023)First half 2024 results: AU$0.01 loss per share (improved from AU$0.012 loss in 1H 2023). Revenue: AU$1.86m (up 85% from 1H 2023). Net loss: AU$2.41m (loss narrowed 2.6% from 1H 2023).Reported Earnings • Oct 03Full year 2023 earnings released: AU$0.024 loss per share (vs AU$0.017 loss in FY 2022)Full year 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.017 loss in FY 2022). Revenue: AU$2.85m (up 297% from FY 2022). Net loss: AU$5.06m (loss widened 50% from FY 2022).Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.024 loss per share (vs AU$0.017 loss in FY 2022)Full year 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.017 loss in FY 2022). Revenue: AU$2.85m (up 297% from FY 2022). Net loss: AU$5.06m (loss widened 50% from FY 2022).Reported Earnings • Feb 24First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.006 loss in 1H 2022)First half 2023 results: AU$0.012 loss per share (further deteriorated from AU$0.006 loss in 1H 2022). Revenue: AU$1.01m (up 146% from 1H 2022). Net loss: AU$2.47m (loss widened 88% from 1H 2022).모든 업데이트 보기Recent updatesNew Risk • Feb 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$6.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.5m free cash flow). Earnings have declined by 31% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$2.5m revenue, or US$1.8m). Market cap is less than US$100m (AU$44.2m market cap, or US$31.3m).Board Change • Feb 04Less than half of directors are independentFollowing Non-Executive Director Mark McConnell's arrival on 01 February 2026, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director & Consultant John Hurrell was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Oct 29BCAL Diagnostics Limited, Annual General Meeting, Nov 28, 2025BCAL Diagnostics Limited, Annual General Meeting, Nov 28, 2025. Location: at gadens level 29 8 chifley square, sydney nsw 2000 Australia공시 • Oct 21BCAL Diagnostics Limited announced that it expects to receive AUD 10 million in fundingBCAL Diagnostics Limited announced a private placement of Convertible Notes for gross proceeds AUD 10,000,000 on October 20, 2025. The notes have interest rate of 10% per annum and matures on 2 years from the Notes’ issue date. The transaction subject to shareholder approval. The notes are expected to be issued on November 26, 2025. On same day, the company announced it has raised AUD 5,000,000 in its first tranche.Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.02 loss per share (vs AU$0.026 loss in FY 2024)Full year 2025 results: AU$0.02 loss per share. Net loss: AU$7.24m (loss widened 13% from FY 2024).공시 • Mar 25BCAL Diagnostics Limited Announces the Commercial Launch of BREASTEST PlusBCAL Diagnostics Limited announced the commercial launch of BREASTEST plus. This first-in-class blood test is available from 27 March 2025 and will be used alongside standard-of-care imaging in breast cancer screening and diagnostics. The Company is pleased that this launch has been achieved within the previously announced target timeframe of having the test commercially available in Australia by the end of first quarter CY2025. BREASTEST plus has been validated to meet the challenge of high breast density, which affects approximately 50% of Australian women participating in breast cancer screening programs. High breast density masks abnormal lesions on mammography, in many cases making it difficult to diagnose. In line with the Company's stated market entry strategy, BREASTEST plus will provide clinicians with a new, additional tool to help overcome this longstanding challenge. BREASTEST plus will be available at Sydney Breast Clinic from Thursday this week, with a planned roll out to additional select clinical sites, initially in Sydney and Melbourne, to follow. BCAL is focused on ensuring a systematic national rollout, working closely with clinical partners, to ensure Australian women will have access to BREASTEST plus™?. BCAL collaborated with its Clinical Advisory Board of eminent Australian breast surgeons, radiologists and physicians to develop BREASTEST plus™?, ensuring it meets the needs of women with high breast density who are often the most challenging to diagnose via traditional imaging.New Risk • Mar 24New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$8.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$8.1m free cash flow). Earnings have declined by 43% per year over the past 5 years. Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Minor Risks Revenue is less than US$5m (AU$2.6m revenue, or US$1.6m). Market cap is less than US$100m (AU$42.1m market cap, or US$26.5m).New Risk • Mar 01New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -AU$8.1m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-AU$8.1m). Currently unprofitable and not forecast to become profitable next year (AU$1.4m net loss next year). Revenue is less than US$5m (AU$2.6m revenue, or US$1.6m). Market cap is less than US$100m (AU$36.2m market cap, or US$22.5m).New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 43% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (43% increase in shares outstanding). Minor Risks Revenue is less than US$5m (AU$3.1m revenue, or US$1.9m). Market cap is less than US$100m (AU$34.4m market cap, or US$21.4m).공시 • Oct 04BCAL Diagnostics Limited, Annual General Meeting, Nov 22, 2024BCAL Diagnostics Limited, Annual General Meeting, Nov 22, 2024.Reported Earnings • Aug 31Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: AU$0.026 loss per share (further deteriorated from AU$0.024 loss in FY 2023). Revenue: AU$3.10m (up 8.6% from FY 2023). Net loss: AU$6.40m (loss widened 26% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 62%. Revenue is forecast to grow 78% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.New Risk • Jul 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 68% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$1.5m net loss in 2 years). Revenue is less than US$5m (AU$3.7m revenue, or US$2.4m). Market cap is less than US$100m (AU$41.1m market cap, or US$26.9m).공시 • Jul 25BCAL Diagnostics Limited has completed a Follow-on Equity Offering in the amount of AUD 10.5 million.BCAL Diagnostics Limited has completed a Follow-on Equity Offering in the amount of AUD 10.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 62,000,000 Price\Range: AUD 0.1 Discount Per Security: AUD 0.006 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 43,000,000 Price\Range: AUD 0.1 Discount Per Security: AUD 0.006 Transaction Features: Subsequent Direct ListingNew Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$1.5m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (AU$3.7m revenue, or US$2.5m). Market cap is less than US$100m (AU$44.2m market cap, or US$29.3m).Board Change • Mar 22Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 4 experienced directors. 2 highly experienced directors. 2 independent directors (3 non-independent directors). Co-Founder & Non-Executive Director Ron Phillips is the most experienced director on the board, commencing their role in 2010. Independent Non-Executive Director Mark Burrows was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Reported Earnings • Feb 22First half 2024 earnings released: AU$0.01 loss per share (vs AU$0.012 loss in 1H 2023)First half 2024 results: AU$0.01 loss per share (improved from AU$0.012 loss in 1H 2023). Revenue: AU$1.86m (up 85% from 1H 2023). Net loss: AU$2.41m (loss narrowed 2.6% from 1H 2023).Recent Insider Transactions Derivative • Nov 29Co-Founder & Non-Executive Director exercised options to buy AU$212k worth of stock.On the 23rd of November, Ronald Phillips exercised options to buy 2m shares at a strike price of around AU$0.057, costing a total of AU$116k. This transaction amounted to 8.0% of their direct individual holding at the time of the trade. Since June 2023, Ronald has owned 25.36m shares directly. Company insiders have collectively bought AU$187k more than they sold, via options and on-market transactions, in the last 12 months.공시 • Nov 27BCAL Diagnostics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million.BCAL Diagnostics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,500,000 Price\Range: AUD 0.1 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 500,000 Price\Range: AUD 0.1 Transaction Features: Subsequent Direct Listing공시 • Oct 05BCAL Diagnostics Limited, Annual General Meeting, Nov 22, 2023BCAL Diagnostics Limited, Annual General Meeting, Nov 22, 2023, at 10:00 AUS Eastern Standard Time. Agenda: To consider directors election.Reported Earnings • Oct 03Full year 2023 earnings released: AU$0.024 loss per share (vs AU$0.017 loss in FY 2022)Full year 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.017 loss in FY 2022). Revenue: AU$2.85m (up 297% from FY 2022). Net loss: AU$5.06m (loss widened 50% from FY 2022).공시 • Sep 06Bcal Diagnostics Limited Appoints Shane Ryan as Chief Operating Officer Effective 21 September 2023BCAL Diagnostics Limited announced the appointment of Mr. Shane Ryan as Chief Operating Officer (COO), effective 21 September 2023. Shane will be responsible for the overall operation and administration of BCAL's clinical affairs, physician relationships, clinical product marketing, promotion, strategy, and business development. Before joining BCAL, Shane was most recently the Global Senior Vice President Strategy & Innovation - Patient Access for GenesisCare. Shane has more than 20 years' experience in the global oncology market and in particular breast cancer. He has an extensive Oncology network and deep understanding of what is critically important to both cancer patients, their treating Oncologist, and the extended multidisciplinary team. His experience covers patient care, research, innovative service delivery models, and commercial aspects of cancer patient management. Shane was also responsible for the introduction of the highly successful precision medicine test for Ductal Carcinoma In-situ (DCISionRT), providing access for Australian women for the first time in addition to this 1500 Nation-wide clinical registry. Shane has also originated other clinical trials and evaluations of predictive and management tools for the management of high-risk breast cancer patients in Australia. Prior to joining GenesisCare, Mr. Ryan spent 10 years with globally recognised Peter MacCallum Cancer Centre where he held Executive positions in Clinical Operations, Services Development and Surgery.New Risk • Sep 02New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.4m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 48% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (12% increase in shares outstanding). Revenue is less than US$5m (AU$2.9m revenue, or US$1.8m). Market cap is less than US$100m (AU$24.9m market cap, or US$16.0m).Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.024 loss per share (vs AU$0.017 loss in FY 2022)Full year 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.017 loss in FY 2022). Revenue: AU$2.85m (up 297% from FY 2022). Net loss: AU$5.06m (loss widened 50% from FY 2022).New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 51% per year over the past 5 years. Revenue is less than US$1m (AU$1.3m revenue, or US$844k). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (AU$24.4m market cap, or US$15.7m).분석 기사 • Aug 08Is BCAL Diagnostics (ASX:BDX) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...New Risk • Aug 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 51% per year over the past 5 years. Revenue is less than US$1m (AU$1.3m revenue, or US$862k). Minor Risks Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (AU$25.6m market cap, or US$16.7m).New Risk • Jun 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.9m (US$9.84m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 51% per year over the past 5 years. Revenue is less than US$1m (AU$1.3m revenue, or US$872k). Market cap is less than US$10m (AU$14.9m market cap, or US$9.84m). Minor Risk Shareholders have been diluted in the past year (2.3% increase in shares outstanding).Reported Earnings • Feb 24First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.006 loss in 1H 2022)First half 2023 results: AU$0.012 loss per share (further deteriorated from AU$0.006 loss in 1H 2022). Revenue: AU$1.01m (up 146% from 1H 2022). Net loss: AU$2.47m (loss widened 88% from 1H 2022).Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. 2 highly experienced directors. Co-Founder & Non-Executive Director Ron Phillips is the most experienced director on the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Oct 29BCAL Diagnostics Limited, Annual General Meeting, Nov 29, 2022BCAL Diagnostics Limited, Annual General Meeting, Nov 29, 2022, at 15:00 AUS Eastern Standard Time. Location: Mills Oakley Level 7 151 Clarence Street Sydney NSW 2000 Sydney Nsw 2000 Australia Agenda: To consider remuneration report; to consider re-election of director; to consider ratification of prior issue of shares; and to consider approval of additional 10% of issuance capacity.Reported Earnings • Aug 31Full year 2022 earnings released: AU$0.017 loss per share (vs AU$0.011 loss in FY 2021)Full year 2022 results: AU$0.017 loss per share (down from AU$0.011 loss in FY 2021). Net loss: AU$3.39m (loss widened 122% from FY 2021).Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. 2 highly experienced directors. Co-Founder & Non-Executive Director Ron Phillips is the most experienced director on the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.분석 기사 • Apr 07Companies Like BCAL Diagnostics (ASX:BDX) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Board Change • Apr 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. 2 highly experienced directors. Co-Founder & Non-Executive Director Ron Phillips is the most experienced director on the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Feb 21First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.006 loss per share (down from AU$0.002 loss in 1H 2021). Net loss: AU$1.32m (loss widened 438% from 1H 2021). Revenue was in line with analyst estimates.공시 • Feb 09Bcal Diagnostics Limited Provides Additional Information on Recent Analysis to Distinguish Between Blood Samples of Breast Cancer Patients and Normal Control SamplesBcal Diagnostics Limited provided additional information to supplement the announcement dated 7 February 2022, following analysis of its scientific data carried out independently by its Australian team and by a highly regarded team of international diagnostic experts. BCAL Diagnostics provided scientific data on Cohorts 1, 2, 3, and 4, to be independently reviewed and retrospectively analysed in a strategic collaboration with BSC-Medical from the United States, involving Dr Szilard Voros, and Dr Aruna Bansal. Both experts have a proven track record in developing IVDs. BSC analysed the data in a blinded fashion, without any access to prior in-house results. In this formal analysis conducted pursuant to a pre-specified Statistical Analysis Plan, candidate signatures were developed for five discovery sets. Overall, twelve lipids selected, with two lipids selected multiple times: lipid 1 and lipid 2. Each candidate signature contained one or both of these lipids, and each candidate signature was supported by Area Under the Curve (AUC) > 70% in at least one other dataset. Two specific signatures developed for cohort 4 and combined cohorts 2+3+4 showed strong performance in the validations sets. To clarify, the cohort 4 signature was well supported by cohorts 2 and 3 with impressive AUC of 78% and 85% respectively. The cohort 2+3+4 signature was well supported by the 2+3+4 validation set with AUC of 83%. Acknowledging that the patients overlapped, these two signatures were very similar in composition, had only three lipids each, and two of the lipids were consistent, with a third lipid for each signature from one class of lipids. The supportive lipids were highly correlated. The findings demonstrated strikingly internally consistent results across all datasets. An overall accuracy of 77% was achieved in independent validation. The results are especially exciting because when testing a signature on a never seen before data set, a considerable drop in performance (15-20% based on empirical testing) from training to testing sets is frequently observed while the algorithm is being developed and fine-tuned, which was not the case here for cohort 4 and the combined cohort 2+3+4 results. This lends itself to the strength of the identified signatures. An in-house comparison of the 12 lipids identified by Dr Bansal to BCAL's results showed a 50% overlap despite the use of very different approaches. Furthermore, the 2 lipids in the most promising signatures identified by Bansal are part of BCAL's 18 lipid panel and 2 of the 12 are part of BCAL's locally optimised 6- lipid signature. This is a significant outcome given that the 12 lipids were identified out of 400+ candidates and half of them were mutually identified. In summary, the outcome of the analysis by the two teams is that a considerably reduced number of markers, compared with previous information, can be used to distinguish between blood samples of breast cancer patients and normal control samples. Such a reduction in the number of markers to be examined for each test considerably improves its commercial feasibility and attractiveness, reducing the time, cost and difficulty of analysis of each sample.공시 • Feb 08Bcal Diagnostics Limited Announces Recent Analysis Significantly Improves Commercial ProspectsBCAL Diagnostics Limited reported recent results of analysis of its scientific data carried out independently by its Australian team and by a highly regarded team of international diagnostic experts. The outcome of the analysis by the two teams is that a considerably reduced number of markers, compared with previous information, can be used to distinguish between blood samples of breast cancer patients and normal control samples. BCAL is developing a blood-based test for detection of breast cancer in its early stages. The test is based on disease-associated changes in the profile of lipids (fats) found in blood. As described in the Prospectus for its 2021 IPO, the Company had at that time collected information on blood samples from 3 cohorts of women diagnosed with breast cancer compared with healthy controls. As a result, a panel of 18 different lipids, differing in their amounts between cancer and non-cancer blood samples, had been identified. Over the past 6 months, samples from a 4th cohort of patients have been examined, bringing the total of samples analysed in Australia since 2018 to 790. Examination of the data from the 4th cohort by the Company's Australian team indicated that a signature with a reduced number of lipid markers than the original 18, as few as 6 to 10, might be sufficient for an effective clinical test. Such a reduction in the number of markers to be examined for each test considerably improves its commercial feasibility and attractiveness, reducing the time, cost and difficulty for analysis of each sample. Independently, BCAL contracted a third party to review the BCAL data and perform a retrospective analysis for the entire 790 samples collected. The review identified five small lipid signatures, with two particularly strong signatures whose performance strongly characterised samples from breast cancer patients when compared with normal controls. These signatures delivered strikingly consistent performance and are in agreement with BCAL's local blind testing findings. The combination of these local and international analyses supports BCAL's goal of reaching a refined algorithm, facilitating acceleration of test development in a format that will be attractive both clinically and commercially. In addition, this greater refinement of the lipid marker panel has opened up the opportunity for BCAL to secure additional patent protection for its test.분석 기사 • Dec 23Here's Why We're Not Too Worried About BCAL Diagnostics' (ASX:BDX) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Reported Earnings • Sep 06Full year 2021 earnings released: AU$0.011 loss per share (vs AU$0.006 loss in FY 2020)Full year 2021 results: Net loss: AU$1.52m (loss widened 119% from FY 2020).공시 • Sep 03BCAL Diagnostics Limited Commences Collecting Samples for the First Stage of Its Australian Clinical ProgramBCAL Diagnostics Limited announced that it has commenced collecting samples for the first stage of its Australian clinical program, to be used for validation and performance evaluation of its blood-based test for detection of breast cancer. In the first instance the test is being trialled for use as an adjunct to mammography, to help improve the accuracy of this commonly used diagnostic approach. This trial will confirm the set of candidate markers used in its breast cancer diagnostic test to distinguish between healthy women and those affected with breast cancer, as well as informing the design of the following pivotal clinical trial which will underpin regulatory approval.매출 및 비용 세부 내역BCAL Diagnostics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이ASX:BDX 매출, 비용 및 순이익 (AUD Millions)날짜매출순이익일반관리비연구개발비31 Dec 253-74530 Sep 253-74530 Jun 253-74431 Mar 253-85431 Dec 243-85430 Sep 243-75430 Jun 243-64431 Mar 243-64431 Dec 234-54430 Sep 233-53430 Jun 233-53431 Mar 232-53431 Dec 221-52330 Sep 221-42330 Jun 221-32231 Mar 221-31231 Dec 211-31230 Sep 210-21130 Jun 210-21131 Mar 210-11031 Dec 20101030 Sep 200-11030 Jun 200-11030 Jun 19000030 Jun 180000양질의 수익: BDX 은(는) 현재 수익성이 없습니다.이익 마진 증가: BDX는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BDX은 수익성이 없으며 지난 5년 동안 손실이 연평균 30.8% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BDX의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BDX은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(12.7%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BDX는 현재 수익성이 없으므로 자본 수익률이 음수(-286.61%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 08:20종가2026/05/22 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BCAL Diagnostics Limited는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Rosemary CumminsMST Financial Services Pty Limited
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.02 loss per share (vs AU$0.026 loss in FY 2024)Full year 2025 results: AU$0.02 loss per share. Net loss: AU$7.24m (loss widened 13% from FY 2024).
Reported Earnings • Aug 31Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: AU$0.026 loss per share (further deteriorated from AU$0.024 loss in FY 2023). Revenue: AU$3.10m (up 8.6% from FY 2023). Net loss: AU$6.40m (loss widened 26% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 62%. Revenue is forecast to grow 78% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Reported Earnings • Feb 22First half 2024 earnings released: AU$0.01 loss per share (vs AU$0.012 loss in 1H 2023)First half 2024 results: AU$0.01 loss per share (improved from AU$0.012 loss in 1H 2023). Revenue: AU$1.86m (up 85% from 1H 2023). Net loss: AU$2.41m (loss narrowed 2.6% from 1H 2023).
Reported Earnings • Oct 03Full year 2023 earnings released: AU$0.024 loss per share (vs AU$0.017 loss in FY 2022)Full year 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.017 loss in FY 2022). Revenue: AU$2.85m (up 297% from FY 2022). Net loss: AU$5.06m (loss widened 50% from FY 2022).
Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.024 loss per share (vs AU$0.017 loss in FY 2022)Full year 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.017 loss in FY 2022). Revenue: AU$2.85m (up 297% from FY 2022). Net loss: AU$5.06m (loss widened 50% from FY 2022).
Reported Earnings • Feb 24First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.006 loss in 1H 2022)First half 2023 results: AU$0.012 loss per share (further deteriorated from AU$0.006 loss in 1H 2022). Revenue: AU$1.01m (up 146% from 1H 2022). Net loss: AU$2.47m (loss widened 88% from 1H 2022).
New Risk • Feb 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$6.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.5m free cash flow). Earnings have declined by 31% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$2.5m revenue, or US$1.8m). Market cap is less than US$100m (AU$44.2m market cap, or US$31.3m).
Board Change • Feb 04Less than half of directors are independentFollowing Non-Executive Director Mark McConnell's arrival on 01 February 2026, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director & Consultant John Hurrell was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Oct 29BCAL Diagnostics Limited, Annual General Meeting, Nov 28, 2025BCAL Diagnostics Limited, Annual General Meeting, Nov 28, 2025. Location: at gadens level 29 8 chifley square, sydney nsw 2000 Australia
공시 • Oct 21BCAL Diagnostics Limited announced that it expects to receive AUD 10 million in fundingBCAL Diagnostics Limited announced a private placement of Convertible Notes for gross proceeds AUD 10,000,000 on October 20, 2025. The notes have interest rate of 10% per annum and matures on 2 years from the Notes’ issue date. The transaction subject to shareholder approval. The notes are expected to be issued on November 26, 2025. On same day, the company announced it has raised AUD 5,000,000 in its first tranche.
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.02 loss per share (vs AU$0.026 loss in FY 2024)Full year 2025 results: AU$0.02 loss per share. Net loss: AU$7.24m (loss widened 13% from FY 2024).
공시 • Mar 25BCAL Diagnostics Limited Announces the Commercial Launch of BREASTEST PlusBCAL Diagnostics Limited announced the commercial launch of BREASTEST plus. This first-in-class blood test is available from 27 March 2025 and will be used alongside standard-of-care imaging in breast cancer screening and diagnostics. The Company is pleased that this launch has been achieved within the previously announced target timeframe of having the test commercially available in Australia by the end of first quarter CY2025. BREASTEST plus has been validated to meet the challenge of high breast density, which affects approximately 50% of Australian women participating in breast cancer screening programs. High breast density masks abnormal lesions on mammography, in many cases making it difficult to diagnose. In line with the Company's stated market entry strategy, BREASTEST plus will provide clinicians with a new, additional tool to help overcome this longstanding challenge. BREASTEST plus will be available at Sydney Breast Clinic from Thursday this week, with a planned roll out to additional select clinical sites, initially in Sydney and Melbourne, to follow. BCAL is focused on ensuring a systematic national rollout, working closely with clinical partners, to ensure Australian women will have access to BREASTEST plus™?. BCAL collaborated with its Clinical Advisory Board of eminent Australian breast surgeons, radiologists and physicians to develop BREASTEST plus™?, ensuring it meets the needs of women with high breast density who are often the most challenging to diagnose via traditional imaging.
New Risk • Mar 24New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$8.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$8.1m free cash flow). Earnings have declined by 43% per year over the past 5 years. Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Minor Risks Revenue is less than US$5m (AU$2.6m revenue, or US$1.6m). Market cap is less than US$100m (AU$42.1m market cap, or US$26.5m).
New Risk • Mar 01New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -AU$8.1m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-AU$8.1m). Currently unprofitable and not forecast to become profitable next year (AU$1.4m net loss next year). Revenue is less than US$5m (AU$2.6m revenue, or US$1.6m). Market cap is less than US$100m (AU$36.2m market cap, or US$22.5m).
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 43% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (43% increase in shares outstanding). Minor Risks Revenue is less than US$5m (AU$3.1m revenue, or US$1.9m). Market cap is less than US$100m (AU$34.4m market cap, or US$21.4m).
공시 • Oct 04BCAL Diagnostics Limited, Annual General Meeting, Nov 22, 2024BCAL Diagnostics Limited, Annual General Meeting, Nov 22, 2024.
Reported Earnings • Aug 31Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: AU$0.026 loss per share (further deteriorated from AU$0.024 loss in FY 2023). Revenue: AU$3.10m (up 8.6% from FY 2023). Net loss: AU$6.40m (loss widened 26% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 62%. Revenue is forecast to grow 78% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
New Risk • Jul 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 68% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$1.5m net loss in 2 years). Revenue is less than US$5m (AU$3.7m revenue, or US$2.4m). Market cap is less than US$100m (AU$41.1m market cap, or US$26.9m).
공시 • Jul 25BCAL Diagnostics Limited has completed a Follow-on Equity Offering in the amount of AUD 10.5 million.BCAL Diagnostics Limited has completed a Follow-on Equity Offering in the amount of AUD 10.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 62,000,000 Price\Range: AUD 0.1 Discount Per Security: AUD 0.006 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 43,000,000 Price\Range: AUD 0.1 Discount Per Security: AUD 0.006 Transaction Features: Subsequent Direct Listing
New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$1.5m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (AU$3.7m revenue, or US$2.5m). Market cap is less than US$100m (AU$44.2m market cap, or US$29.3m).
Board Change • Mar 22Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 4 experienced directors. 2 highly experienced directors. 2 independent directors (3 non-independent directors). Co-Founder & Non-Executive Director Ron Phillips is the most experienced director on the board, commencing their role in 2010. Independent Non-Executive Director Mark Burrows was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Reported Earnings • Feb 22First half 2024 earnings released: AU$0.01 loss per share (vs AU$0.012 loss in 1H 2023)First half 2024 results: AU$0.01 loss per share (improved from AU$0.012 loss in 1H 2023). Revenue: AU$1.86m (up 85% from 1H 2023). Net loss: AU$2.41m (loss narrowed 2.6% from 1H 2023).
Recent Insider Transactions Derivative • Nov 29Co-Founder & Non-Executive Director exercised options to buy AU$212k worth of stock.On the 23rd of November, Ronald Phillips exercised options to buy 2m shares at a strike price of around AU$0.057, costing a total of AU$116k. This transaction amounted to 8.0% of their direct individual holding at the time of the trade. Since June 2023, Ronald has owned 25.36m shares directly. Company insiders have collectively bought AU$187k more than they sold, via options and on-market transactions, in the last 12 months.
공시 • Nov 27BCAL Diagnostics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million.BCAL Diagnostics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,500,000 Price\Range: AUD 0.1 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 500,000 Price\Range: AUD 0.1 Transaction Features: Subsequent Direct Listing
공시 • Oct 05BCAL Diagnostics Limited, Annual General Meeting, Nov 22, 2023BCAL Diagnostics Limited, Annual General Meeting, Nov 22, 2023, at 10:00 AUS Eastern Standard Time. Agenda: To consider directors election.
Reported Earnings • Oct 03Full year 2023 earnings released: AU$0.024 loss per share (vs AU$0.017 loss in FY 2022)Full year 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.017 loss in FY 2022). Revenue: AU$2.85m (up 297% from FY 2022). Net loss: AU$5.06m (loss widened 50% from FY 2022).
공시 • Sep 06Bcal Diagnostics Limited Appoints Shane Ryan as Chief Operating Officer Effective 21 September 2023BCAL Diagnostics Limited announced the appointment of Mr. Shane Ryan as Chief Operating Officer (COO), effective 21 September 2023. Shane will be responsible for the overall operation and administration of BCAL's clinical affairs, physician relationships, clinical product marketing, promotion, strategy, and business development. Before joining BCAL, Shane was most recently the Global Senior Vice President Strategy & Innovation - Patient Access for GenesisCare. Shane has more than 20 years' experience in the global oncology market and in particular breast cancer. He has an extensive Oncology network and deep understanding of what is critically important to both cancer patients, their treating Oncologist, and the extended multidisciplinary team. His experience covers patient care, research, innovative service delivery models, and commercial aspects of cancer patient management. Shane was also responsible for the introduction of the highly successful precision medicine test for Ductal Carcinoma In-situ (DCISionRT), providing access for Australian women for the first time in addition to this 1500 Nation-wide clinical registry. Shane has also originated other clinical trials and evaluations of predictive and management tools for the management of high-risk breast cancer patients in Australia. Prior to joining GenesisCare, Mr. Ryan spent 10 years with globally recognised Peter MacCallum Cancer Centre where he held Executive positions in Clinical Operations, Services Development and Surgery.
New Risk • Sep 02New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.4m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 48% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (12% increase in shares outstanding). Revenue is less than US$5m (AU$2.9m revenue, or US$1.8m). Market cap is less than US$100m (AU$24.9m market cap, or US$16.0m).
Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.024 loss per share (vs AU$0.017 loss in FY 2022)Full year 2023 results: AU$0.024 loss per share (further deteriorated from AU$0.017 loss in FY 2022). Revenue: AU$2.85m (up 297% from FY 2022). Net loss: AU$5.06m (loss widened 50% from FY 2022).
New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 51% per year over the past 5 years. Revenue is less than US$1m (AU$1.3m revenue, or US$844k). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (AU$24.4m market cap, or US$15.7m).
분석 기사 • Aug 08Is BCAL Diagnostics (ASX:BDX) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
New Risk • Aug 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 51% per year over the past 5 years. Revenue is less than US$1m (AU$1.3m revenue, or US$862k). Minor Risks Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (AU$25.6m market cap, or US$16.7m).
New Risk • Jun 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.9m (US$9.84m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 51% per year over the past 5 years. Revenue is less than US$1m (AU$1.3m revenue, or US$872k). Market cap is less than US$10m (AU$14.9m market cap, or US$9.84m). Minor Risk Shareholders have been diluted in the past year (2.3% increase in shares outstanding).
Reported Earnings • Feb 24First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.006 loss in 1H 2022)First half 2023 results: AU$0.012 loss per share (further deteriorated from AU$0.006 loss in 1H 2022). Revenue: AU$1.01m (up 146% from 1H 2022). Net loss: AU$2.47m (loss widened 88% from 1H 2022).
Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. 2 highly experienced directors. Co-Founder & Non-Executive Director Ron Phillips is the most experienced director on the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Oct 29BCAL Diagnostics Limited, Annual General Meeting, Nov 29, 2022BCAL Diagnostics Limited, Annual General Meeting, Nov 29, 2022, at 15:00 AUS Eastern Standard Time. Location: Mills Oakley Level 7 151 Clarence Street Sydney NSW 2000 Sydney Nsw 2000 Australia Agenda: To consider remuneration report; to consider re-election of director; to consider ratification of prior issue of shares; and to consider approval of additional 10% of issuance capacity.
Reported Earnings • Aug 31Full year 2022 earnings released: AU$0.017 loss per share (vs AU$0.011 loss in FY 2021)Full year 2022 results: AU$0.017 loss per share (down from AU$0.011 loss in FY 2021). Net loss: AU$3.39m (loss widened 122% from FY 2021).
Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. 2 highly experienced directors. Co-Founder & Non-Executive Director Ron Phillips is the most experienced director on the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
분석 기사 • Apr 07Companies Like BCAL Diagnostics (ASX:BDX) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Board Change • Apr 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. 2 highly experienced directors. Co-Founder & Non-Executive Director Ron Phillips is the most experienced director on the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Feb 21First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.006 loss per share (down from AU$0.002 loss in 1H 2021). Net loss: AU$1.32m (loss widened 438% from 1H 2021). Revenue was in line with analyst estimates.
공시 • Feb 09Bcal Diagnostics Limited Provides Additional Information on Recent Analysis to Distinguish Between Blood Samples of Breast Cancer Patients and Normal Control SamplesBcal Diagnostics Limited provided additional information to supplement the announcement dated 7 February 2022, following analysis of its scientific data carried out independently by its Australian team and by a highly regarded team of international diagnostic experts. BCAL Diagnostics provided scientific data on Cohorts 1, 2, 3, and 4, to be independently reviewed and retrospectively analysed in a strategic collaboration with BSC-Medical from the United States, involving Dr Szilard Voros, and Dr Aruna Bansal. Both experts have a proven track record in developing IVDs. BSC analysed the data in a blinded fashion, without any access to prior in-house results. In this formal analysis conducted pursuant to a pre-specified Statistical Analysis Plan, candidate signatures were developed for five discovery sets. Overall, twelve lipids selected, with two lipids selected multiple times: lipid 1 and lipid 2. Each candidate signature contained one or both of these lipids, and each candidate signature was supported by Area Under the Curve (AUC) > 70% in at least one other dataset. Two specific signatures developed for cohort 4 and combined cohorts 2+3+4 showed strong performance in the validations sets. To clarify, the cohort 4 signature was well supported by cohorts 2 and 3 with impressive AUC of 78% and 85% respectively. The cohort 2+3+4 signature was well supported by the 2+3+4 validation set with AUC of 83%. Acknowledging that the patients overlapped, these two signatures were very similar in composition, had only three lipids each, and two of the lipids were consistent, with a third lipid for each signature from one class of lipids. The supportive lipids were highly correlated. The findings demonstrated strikingly internally consistent results across all datasets. An overall accuracy of 77% was achieved in independent validation. The results are especially exciting because when testing a signature on a never seen before data set, a considerable drop in performance (15-20% based on empirical testing) from training to testing sets is frequently observed while the algorithm is being developed and fine-tuned, which was not the case here for cohort 4 and the combined cohort 2+3+4 results. This lends itself to the strength of the identified signatures. An in-house comparison of the 12 lipids identified by Dr Bansal to BCAL's results showed a 50% overlap despite the use of very different approaches. Furthermore, the 2 lipids in the most promising signatures identified by Bansal are part of BCAL's 18 lipid panel and 2 of the 12 are part of BCAL's locally optimised 6- lipid signature. This is a significant outcome given that the 12 lipids were identified out of 400+ candidates and half of them were mutually identified. In summary, the outcome of the analysis by the two teams is that a considerably reduced number of markers, compared with previous information, can be used to distinguish between blood samples of breast cancer patients and normal control samples. Such a reduction in the number of markers to be examined for each test considerably improves its commercial feasibility and attractiveness, reducing the time, cost and difficulty of analysis of each sample.
공시 • Feb 08Bcal Diagnostics Limited Announces Recent Analysis Significantly Improves Commercial ProspectsBCAL Diagnostics Limited reported recent results of analysis of its scientific data carried out independently by its Australian team and by a highly regarded team of international diagnostic experts. The outcome of the analysis by the two teams is that a considerably reduced number of markers, compared with previous information, can be used to distinguish between blood samples of breast cancer patients and normal control samples. BCAL is developing a blood-based test for detection of breast cancer in its early stages. The test is based on disease-associated changes in the profile of lipids (fats) found in blood. As described in the Prospectus for its 2021 IPO, the Company had at that time collected information on blood samples from 3 cohorts of women diagnosed with breast cancer compared with healthy controls. As a result, a panel of 18 different lipids, differing in their amounts between cancer and non-cancer blood samples, had been identified. Over the past 6 months, samples from a 4th cohort of patients have been examined, bringing the total of samples analysed in Australia since 2018 to 790. Examination of the data from the 4th cohort by the Company's Australian team indicated that a signature with a reduced number of lipid markers than the original 18, as few as 6 to 10, might be sufficient for an effective clinical test. Such a reduction in the number of markers to be examined for each test considerably improves its commercial feasibility and attractiveness, reducing the time, cost and difficulty for analysis of each sample. Independently, BCAL contracted a third party to review the BCAL data and perform a retrospective analysis for the entire 790 samples collected. The review identified five small lipid signatures, with two particularly strong signatures whose performance strongly characterised samples from breast cancer patients when compared with normal controls. These signatures delivered strikingly consistent performance and are in agreement with BCAL's local blind testing findings. The combination of these local and international analyses supports BCAL's goal of reaching a refined algorithm, facilitating acceleration of test development in a format that will be attractive both clinically and commercially. In addition, this greater refinement of the lipid marker panel has opened up the opportunity for BCAL to secure additional patent protection for its test.
분석 기사 • Dec 23Here's Why We're Not Too Worried About BCAL Diagnostics' (ASX:BDX) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Reported Earnings • Sep 06Full year 2021 earnings released: AU$0.011 loss per share (vs AU$0.006 loss in FY 2020)Full year 2021 results: Net loss: AU$1.52m (loss widened 119% from FY 2020).
공시 • Sep 03BCAL Diagnostics Limited Commences Collecting Samples for the First Stage of Its Australian Clinical ProgramBCAL Diagnostics Limited announced that it has commenced collecting samples for the first stage of its Australian clinical program, to be used for validation and performance evaluation of its blood-based test for detection of breast cancer. In the first instance the test is being trialled for use as an adjunct to mammography, to help improve the accuracy of this commonly used diagnostic approach. This trial will confirm the set of candidate markers used in its breast cancer diagnostic test to distinguish between healthy women and those affected with breast cancer, as well as informing the design of the following pivotal clinical trial which will underpin regulatory approval.